INVA
Innoviva, Inc.NASDAQHealthcare$22.99-1.79%ClosedMarket Cap: $1.48B
As of 2026-04-06
Valuation
P/E (TTM)
5.45
PEG
0.01
P/B
1.47
P/S
3.57
EV/EBITDA
3.21
DCF Value
$64.54
FCF Yield
13.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.9%
Operating Margin
-4.0%
Net Margin
65.4%
ROE
30.6%
ROA
16.6%
ROIC
-0.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $118.0M | 64.1% | $39.0M | $164.2M | $1.94 | — |
| FY 2025 | $425.1M | 72.3% | $163.7M | $271.2M | $3.30 | — |
| Q3 2025 | $107.8M | 76.1% | $34.6M | $89.9M | $1.08 | — |
| Q2 2025 | $100.3M | 89.4% | $-48.8M | $63.7M | $0.77 | — |
| Q1 2025 | $88.6M | 90.0% | $-41.4M | $-46.6M | $-0.74 | — |
| Q4 2024 | $91.8M | 92.2% | $43.1M | $20.3M | $0.24 | — |
| FY 2024 | $358.7M | 89.8% | $166.9M | $23.4M | $0.36 | — |
| Q3 2024 | $89.5M | 88.8% | $49.7M | $1.2M | $0.02 | — |
| Q2 2024 | $103.4M | 82.2% | $54.7M | $-34.7M | $-0.55 | — |
| Q1 2024 | $77.5M | 85.8% | $25.8M | $36.5M | $0.46 | — |
| Q4 2023 | $85.8M | 84.7% | $37.5M | $61.5M | $0.76 | — |
| FY 2023 | $310.5M | 86.3% | $113.9M | $179.7M | $2.20 | — |